How to appeal an Aetna atopic dermatitis (ad / eczema) denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for atopic dermatitis (ad / eczema)

Cited policy: Aetna CPB on Adbry (Tralokinumab) for AD

Age >=12 yr per Dec 2023 expansion. Moderate-severe AD with IGA >=3 OR EASI >=16. Inadequate response to topical CS + TCI. Step-therapy: failure or intolerance to Dupixent OR contraindication. Reauth at 16 wk with EASI-50 or IGA improvement.

How Aetna denies atopic dermatitis (ad / eczema) — and how to counter it

Where Aetna pushes back: 1) Must fail Dupixent first (step-therapy); 2) Use Dupixent — same class.

Counter-arguments that hold up: Adbry IL-13-specific; Dupixent blocks IL-4Rα (both 4 and 13) — DISTINCT mechanisms. AAD 2024 + ETFAD/EADV 2024 list as PARALLEL options after topical failure — no mandated Dupixent-first sequence. ECZTRA-1 / ECZTRA-2 (Wollenberg BJD 2021) + ECZTRA-3 (with TCS) + ECZTRA-6 (ages 12-17 — supports Dec 2023 expansion) demonstrate independent efficacy. Indicated when Dupixent ineligible (conjunctivitis AE, facial dermatitis paradox) or when IL-13-monotherapy preferred.

What Aetna typically denies for atopic dermatitis (ad / eczema)

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For atopic dermatitis (ad / eczema), expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the atopic dermatitis (ad / eczema) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Dupixent (AD)
• Adbry
• Ebglyss
• Nemluvio (AD)
• Cibinqo
• Rinvoq (AD)

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.